Drugs / 1A46
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05987605 | Sep 2023 → Aug 2024 | cancer | BioRay Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05348889 | Aug 2022 → Oct 2024 | acute lymphoblastic leukemia | Chimagen Biosciences, Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1A46 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05348889 ↗ |
| Modality | Other / unclassified | “triple-specific T-cell engager 1A46” NCT05987605 ↗ |
| Route | Intravenous | “Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).” NCT05348889 ↗ |